Mirae Asset Mutual Fund trimmed its Lupin Limited stake from 1.83% to 1.74%, selling 406,904 shares.
An innovation-led pharmaceutical company headquartered in Mumbai, Lupin develops and commercializes a broad range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The company operates as a transnational enterprise, serving customers across more than 100 markets including the United States, India, South Africa, Asia Pacific, Latin America, Europe, and the Middle East regions.
Indian arm of South Korea's Mirae Asset Global Investments, one of Asia's largest asset managers. Manages over Rs 2.5 lakh crore in India across equity and hybrid funds. CIO Neelesh Surana has built a reputation for rigorous bottom-up stock selection with a long-term quality growth bias. Mirae Asset Emerging Bluechip Fund built a cult following before being closed to fresh investments due to size.
